Vas Narasimhan

Q: What types of brand work does Vas Narasimhan do?

Brand Partnerships, Campaign collaborations, endorsements, social media activations, commercials (TV/digital), voiceovers, and media appearances.

Q: What influences pricing for brand deals?

Usage rights, exclusivity, deliverables, campaign length, timelines, and production scope.

Q: What information do you need for a proposal?

Please share your brand, campaign objectives, deliverables, usage period/territory, deadlines, and budget range.

Q: Can Vas Narasimhan create custom content for our campaign?

Yes — Vas Narasimhan can deliver bespoke content (videos, posts, appearances, endorsements) aligned to your creative brief.

Q: Does Vas Narasimhan do voiceovers or on-camera work?

Yes — subject to concept approval and scheduling.

Q: Can Vas Narasimhan also participate in other types of events or campaigns?

Yes — many of our talent are versatile and can engage in speaking engagement, or media/brand activations, depending on their individual skills and availability.

HomeBookingsTalent

Vas Narasimhan has transitioned from a medical doctor to the Chief Executive Officer of a global pharmaceutical company, driving innovation and strategic transformation in the healthcare industry. After earning his M.D. from Harvard Medical School and a master’s degree in public policy from the John F. Kennedy School of Government, Vas Narasimhan dedicated his early career to critical public health initiatives.

From 2012 to 2014, he was Global Head of Development for Novartis Vaccines in the US, then Global Head of Biopharmaceuticals and Oncology Injectables at Sandoz in 2014. His trajectory continued as Global Head of Development for Novartis Pharmaceuticals (2014-2016) and Chief Medical Officer for Novartis AG (2016-2018), roles pivotal to his later leadership. In 2018, Narasimhan was appointed Chief Executive Officer of Novartis, initiating a profound strategic and cultural transformation. Under his leadership, Novartis prioritized key therapeutic areas and advanced technology platforms, including siRNA, radioligand, and gene and cell therapies.

He spearheaded a comprehensive digital revolution, integrating data science and technology to enhance drug discovery, development, and operational efficiency. His tenure oversaw major portfolio shifts, including divestment of the consumer healthcare venture to GSK, the spin-off of Alcon, and exiting a Roche stake. Concurrently, Narasimhan strategically acquired companies like Advanced Accelerator Applications, Endocyte, AveXis, and The Medicines Company, strengthening Novartiss innovative medicines pipeline. He also implemented stricter governance and linked executive bonuses to ethical conduct.

Beyond corporate leadership, Narasimhan holds significant roles in global health and industry governance. He serves as Chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) for 2023-2024, advocating for the biopharmaceutical industry. Since 2022, he has been Chair of the African Parks Network, demonstrating ongoing commitment to global conservation. His contributions are further recognized by anticipated inclusion on the prestigious 2025 TIME100 Health list.